Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Comment by clear2012on Mar 04, 2013 12:47pm
180 Views
Post# 21074432

RE: RE: AURIZON ENTERS INTO DEFINITIVE AGREEMENT W

RE: RE: AURIZON ENTERS INTO DEFINITIVE AGREEMENT W

ARZ being bought is really good for the company. The JV has lost some time to perform and now has a short fuse as September is coming up. So either Heckla stays in the JV (see payments due below) or NOX gets 100% of the deposit back. Both are excellent options for NOX.

- The resource payment is due 60 days after NOX delivers final 43-101. If the year 2 43-101 is the final one (due in April) then I believe the resource payment of approx $50,000,000 and year 3 payment of $9,000,000 for exploration would be due in early September. (Date tied to first agreed budget – I think Sept 7)

Part of the JV agreement is that ARZ/Heckla cannot make hostile takeover until 6 months after JV ends, unless there is a bid from someone else. Something will probably happen this year, there is too much gold in the ground/engineering for building a mine for NOX to sit for this cheap for long. GLTA

<< Previous
Bullboard Posts
Next >>